title: Consideration of Preventing Local Venous Pain by Dacarbazine.
abstract: Local venous pain caused by dacarbazine (DTIC) injection is due to its photodegradation product 5-diazoimidazole-4-carboxamide (Diazo-IC). The production of Diazo-IC can be decreased by protecting the drug from light. Furthermore, the production of Diazo-IC reportedly increases with time; however, there are no studies reporting the association between the injection preparation time and local venous pain caused by the DTIC injection. We evaluated the efficacy of the following: (1) method used to shorten the injection preparation time and (2) method used to change the diluting solution for DTIC. We found that shortening the injection preparation time tended to decrease the local venous pain expression due to DTIC, and Veen F decreased the production of Diazo-IC compared with the normal saline and 5% glucose solution. These results indicate that shortening the injection preparation time may be effective in preventing the local venous pain caused by the DTIC injection; moreover, using Veen F for DTIC may also reduce the pain.
authors.affiliation: Department of Pharmacy, Japanese Red Cross Kyoto Daini Hospital.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Ohtsubo
authors.forename: Takumi
authors.initials: T
authors.lastname: Tsuji
authors.forename: Takayo
authors.initials: T
authors.lastname: Umeyama
authors.forename: Miho
authors.initials: M
authors.lastname: Sudou
authors.forename: Kana
authors.initials: K
authors.lastname: Komesu
authors.forename: Minako
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Yuya
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Rie
authors.initials: R
authors.lastname: Banno
authors.forename: Kanji
authors.initials: K
authors.lastname: Tomogane
authors.forename: Atsuo
authors.initials: A
authors.lastname: Fujita
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Kohno
authors.forename: Tadashi
authors.initials: T
authors.lastname: Mikami
mesh_terms: D001391:Azo Compounds / Q000009:adverse effects* / Q000737:chemistry; D003606:Dacarbazine / Q000009:adverse effects* / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods*; D005950:Glucose Solution, Hypertonic; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000737:chemistry; D007275:Injections, Intravenous / Q000009:adverse effects; D010146:Pain / Q000209:etiology* / Q000517:prevention & control*; D010782:Photolysis; D012965:Sodium Chloride; D013997:Time Factors; D014680:Veins
chemical_list: D001391:Azo Compounds; D005950:Glucose Solution, Hypertonic; D007093:Imidazoles; D012965:Sodium Chloride; D003606:Dacarbazine; C000618831:5-diazoimidazole-4-carboxamide